Using ultrasound microvessel imaging to evaluate ovarian and adnexal lesions
Official title: Ultrasound Imaging of Ovarian and Adnexal Lesions
Run by Mayo Clinic · NCT07280312 · Data updated 2026-11-12
This test tries to see if ultrasound microvessel imaging can better detect small blood vessels in adults scheduled for surgery for ovarian or adnexal lesions.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 40 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | January 22, 2026 |
| Main results expected | December 17, 2027 |
| Study ends | December 17, 2029 |
| Registry record updated | February 3, 2026 |
| Trial ID | NCT07280312 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult women (age 18 or older) who are scheduled for surgical treatment of an ovarian or adnexal lesion and who are not pregnant, have not previously had the lesion removed, and are not receiving neoadjuvant chemotherapy are ideal candidates.
✕Probably not a fit
People who are not planning surgery, who are pregnant, who already had their lesion removed, or who are receiving neoadjuvant systemic therapy are unlikely to benefit from this imaging study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional imaging study adds ultrasound microvessel imaging (UMI) to standard transvaginal ultrasound for adults who are already scheduled for surgical removal of an ovarian or adnexal lesion. Participants will undergo UMI before their planned surgery, and the imaging findings will be compared with the surgical and pathological results to determine how well UMI identifies microvascular patterns associated with malignancy. The study excludes pregnant patients, those who have already had the lesion removed, and patients receiving neoadjuvant systemic therapy. All imaging and care are performed at Mayo Clinic in Rochester, Minnesota.
Why it matters
Potential benefit: If successful, UMI could help distinguish benign from malignant adnexal lesions before surgery and improve preoperative planning.
How similar studies have gone: UMI is a newer ultrasound technique with some preliminary work showing improved detection of small vessels in other settings, but its accuracy for ovarian and adnexal lesions is still largely unproven and being actively studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female patients aged ≥ 18 years * Scheduled for surgery for ovarian or adnexal lesions Exclusion Criteria: * Prior surgical removal of ovarian or adnexal lesions * Undergoing neoadjuvant chemotherapy or targeted systemic therapy * Vulnerable populations, including prisoners, adults lacking capacity to consent, and pregnant women (our study coordinator will ask participants if they are pregnant; if uncertain, a urine pregnancy test will be offered at no cost).
Where it's running
-
Mayo Clinic in Rochester
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Shigao D. Chen, PhD — Mayo Clinic
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Overcoming immune suppression and rebalancing the immune response in ovarian cancer
We will try to find and reverse immune suppression by analyzing bone marrow, blood, spleen, peritoneal fluid, and tumor samples from women having surgery for ovarian cancer.
-
Evaluating NKT3964 for Adults with Advanced Solid Tumors
This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.
-
Testing a new communication tool for ovarian cancer patients and their caregivers
This study is testing a new communication tool to see if it helps ovarian cancer patients, their caregivers, and doctors work better together in planning care.
-
Improving diagnosis of ovarian cancer using imaging methods
This study is trying to improve how doctors diagnose ovarian cancer by using different imaging techniques and descriptions to better tell the difference between harmless and harmful growths in the ovaries.
-
Analyzing solid tumors for HLA loss and collecting T cells for CAR T-cell therapy
This study is testing how often solid tumors lose a key protein that helps the immune system recognize them, while also collecting T cells from patients with high-risk cancers to prepare for future CAR T-cell therapy.
-
Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer
This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.